Camstent is a privately funded Cambridge UK- based company, and through its' unique anti-microbial polymer coating technology is able to dramatically reduce biofilms on consumable silicon-based medical devices.
Camstent is addressing a global hospital acquired infection (HAI) epidemic which severely affects patients and hospital economics. HAIs are estimated to cost global healthcare systems up to $10Bn per annum and a large proportion of these are due to urinary tract infections associated with catheter use (CAUTIs).
Reducing biofilms ensures reduction in infection-related issues which cause discomfort to patients, longer hospitalisation, increased usage of anti biotics and higher costs.
Camstent’s first proof of concept device is a coated Foley Catheter which is in clinical studies in the UK. Earlier studies in a cohort of 95 patients have shown between 61%-98% reduction in biofilms on the Camstent-coated catheter.
Camstent is seeking:
Commercial partners for its coated Foley catheters
Collaboration projects for coating of new catheters and potentially other silicon medical device products where infections are an issue
Licensing partners for its unique coating technology